News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Incyte Corporation (INCY) Release: Data Presented at 2013 American Society of Clinical Oncology Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis


6/4/2013 7:41:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Incyte Corporation (Nasdaq: INCY) announced that results from an exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial for Jakafi® (ruxolitinib) were presented today at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Fibrosis of the bone marrow, a cardinal feature of myelofibrosis (MF), was shown to stabilize or reverse after 24 and 48 months of Jakafi treatment in the majority of patients with MF, a magnitude of an effect not seen with long-term treatment with hydroxyurea. Jakafi, an oral JAK1 and JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES